NDC-11 (Package) | NDC-9 (Product) (Descending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
45629-0134-01 | 45629-0134 | Tivozanib | FOTIVDA | 1.34 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | March 10, 2021 | In Use | |
45629-0089-01 | 45629-0089 | Tivozanib | FOTIVDA | 0.89 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | March 10, 2021 | In Use | |
44567-0530-01 | 44567-0530 | cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 5, 2019 | In Use | |
44567-0511-01 | 44567-0511 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 15, 2015 | In Use | |
44567-0510-01 | 44567-0510 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | In Use | |
44567-0509-01 | 44567-0509 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | In Use | |
44567-0507-01 | 44567-0507 | Teniposide | Teniposide | 10.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | April 30, 2013 | In Use | |
44567-0506-01 | 44567-0506 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
44567-0505-01 | 44567-0505 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
44567-0504-01 | 44567-0504 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
44523-0182-08 | 44523-0182 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate Oral Solution | 25.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 28, 2019 | In Use | |
44278-0025-30 | 44278-0025 | EXEMESTANE | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Nov. 22, 2013 | In Use | ||
44206-0458-24 | 44206-0458 | HUMAN IMMUNOGLOBULIN G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan. 1, 2020 | In Use | |
44206-0457-22 | 44206-0457 | Human Immunoglobulin G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan. 1, 2020 | In Use | |
44206-0457-95 | 44206-0457 | Human Immunoglobulin G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan. 1, 2020 | In Use | |
44206-0456-21 | 44206-0456 | HUMAN IMMUNOGLOBULIN G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan. 1, 2020 | In Use | |
44206-0456-94 | 44206-0456 | HUMAN IMMUNOGLOBULIN G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan. 1, 2020 | In Use | |
44087-5000-03 | 44087-5000 | Tepotinib Hydrochloride | TEPMETKO | 225.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | Feb. 3, 2021 | In Use | |
44087-5000-06 | 44087-5000 | Tepotinib Hydrochloride | TEPMETKO | 225.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | Feb. 3, 2021 | In Use | |
44087-4000-00 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-04 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-05 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-06 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-07 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use | |
44087-4000-08 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | April 1, 2019 | In Use |
Found 10,000 results in 12 milliseconds — Export these results